Black Rock Inc. Ventyx Biosciences, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 4,771,657 shares of VTYX stock, worth $10.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,771,657

Previous 3,747,093 27.34%

Holding current value

$10.5 Million

Previous $20.6 Million 46.52%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$2.31 - $5.59 $2.37 Million - $5.73 Million	1,024,564 Added 27.34%	4,771,657 $11 Million
Q1 2024 May 10, 2024	SELL	$1.9 - $10.13 $128,132 - $683,146	-67,438 Reduced 1.77%	3,747,093 $20.6 Million
Q4 2023 Feb 13, 2024	BUY	$2.08 - $31.18 $387,526 - $5.81 Million	186,311 Added 5.14%	3,814,531 $9.42 Million
Q3 2023 Nov 13, 2023	BUY	$29.8 - $40.3 $12 Million - $16.2 Million	401,648 Added 12.45%	3,628,220 $126 Million
Q2 2023 Aug 11, 2023	BUY	$28.53 - $39.55 $33.6 Million - $46.6 Million	1,177,971 Added 57.5%	3,226,572 $106 Million
Q1 2023 May 12, 2023	BUY	$29.51 - $46.65 $2.32 Million - $3.67 Million	78,738 Added 4.0%	2,048,601 $68.6 Million
Q4 2022 Feb 13, 2023	BUY	$24.16 - $36.38 $14.2 Million - $21.4 Million	588,360 Added 42.59%	1,969,863 $64.6 Million
Q3 2022 Nov 14, 2022	BUY	$12.64 - $38.7 $4.1 Million - $12.6 Million	324,314 Added 30.68%	1,381,503 $48.2 Million
Q2 2022 Aug 12, 2022	BUY	$11.95 - $18.75 $6.76 Million - $10.6 Million	565,853 Added 115.17%	1,057,189 $12.9 Million
Q1 2022 May 12, 2022	SELL	$10.0 - $19.98 $33,660 - $67,252	-3,366 Reduced 0.68%	491,336 $6.67 Million
Q4 2021 Feb 10, 2022	BUY	$14.2 - $23.07 $7.02 Million - $11.4 Million	494,702 New	494,702 $9.83 Million

Others Institutions Holding VTYX

# of Institutions

122

Shares Held

57.4M

Call Options Held

222K

Put Options Held

269K

View Full List

About Ventyx Biosciences, Inc.

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $125M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

More about VTYX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account